STAT June 21, 2024
Jason Mast, Matthew Herper

For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy.

On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sarepta’s Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
FDA Clears Emerging Brain PET System
STAT+: Applesauce lead contamination could not have been prevented, top FDA official suggests
Trump’s FDA commissioner on regulating AI
FDA creates communication ‘super office’ at CDRH

Share This Article